Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator by Seini Moimoi | May 31, 2022 | Portfolio News
Endeavor Doses First Patient In Phase 2 Oncology Study Evaluating The Safety And Efficacy Of ENV-101 (Taladegib) by Seini Moimoi | May 25, 2022 | Portfolio News
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update by Seini Moimoi | May 16, 2022 | Uncategorized, Portfolio News
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update by Seini Moimoi | May 12, 2022 | Portfolio News
89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update by Seini Moimoi | May 11, 2022 | Portfolio News
